UNSPSC 51285901: Benurestat

This classification denotes an enzyme inhibitor with the molecular formula C9H9ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9RA9A22Z0W, chemically known as benzamide, 4-chloro-n-(2-(hydroxyamino)-2-oxoethyl)- but more generally known as benurestat, which bears US NIH Compound Identifier 38000. European Medicines Agency schedules Benurestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05738MIG.

The term BENURESTAT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). BENURESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CLC1CCC(C(=O)NCC(=O)NO)CC1.

UNSPSC 51285901 Benurestat is a Commodity code for a specific pharmaceutical active pharmaceutical ingredient, but the recent state and local contract opportunities tagged under this code do not reflect purchases of benurestat itself. Instead, the opportunities posted reflect procurement of finished pharmaceutical products and medical supplies — specifically antibiotic tablets (doxycycline and ciprofloxacin), naloxone, and drug deactivation systems — ordered through piggyback contracts and direct competitive bids by health and emergency-management agencies. State and local governments use this code tier to procure pharmaceutical products for public health stockpiling, emergency preparedness, and community health program distribution, typically through competitive bidding or cooperative purchasing vehicles that allow jurisdictions to leverage existing state or regional master contracts.

The issuing bodies include state health departments and county public-health or emergency-management authorities. The Illinois Department of Public Health executed a $2,999,999.11 award over 12 months plus two optional renewal years through the MMCAP Infuse cooperative purchasing consortium to Chartwell Rx LLC for antibiotic tablet supply (IFB process completed August 28, 2026). Seminole County, Florida posted a competitive bid (IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term with one-year renewal option. Geographic activity clusters in the Southeast (Florida) and Midwest (Illinois), with opportunities posted between June and August 2026. The Illinois procurement moved through award; the Seminole County opportunity carried a July 26, 2023 response deadline noted in the source, which appears to reflect historical posting data rather than current open opportunities.